Relationship between the response to CPT-11/platimun regimen and BCRP DNA Metylation in patients with NSCLC recurrence after surgical resection.

Trial Profile

Relationship between the response to CPT-11/platimun regimen and BCRP DNA Metylation in patients with NSCLC recurrence after surgical resection.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Irinotecan (Primary) ; Platinum complexes
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top